• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DOLUTEGRAVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • DOLUTEGRAVIR chembl:CHEMBL1229211 Approved

    Alternate Names:

    GSK1349572
    TIVICAY
    S-349572
    GSK-1349572
    DOLUTEGRAVIR
    TIVICAY®
    S/GSK1349572
    GSK 1349572
    chemidplus:1051375-16-6
    pubchem.compound:54726191
    chembl:CHEMBL1229211
    rxcui:1433868
    drugbank:08930

    Drug Info:

    (0 More Sources)

    Publications:

    Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics
    Chen S et al., 2014, Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics., Pharmacogenomics
  • DOLUTEGRAVIR   UGT1A1

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24329186


    Sources:
    PharmGKB FDA

  • DOLUTEGRAVIR   ABCG2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28858994


    Sources:
    PharmGKB

  • DOLUTEGRAVIR   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOLUTEGRAVIR   NR1I2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOLUTEGRAVIR   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PharmGKB: dolutegravir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics
    Chen S et al., 2014, Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics., Pharmacogenomics

  • TTD: Dolutegravir

    • Version: 2020.06.01

    Alternate Names:
    D00YZD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1229211

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Dolutegravir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21